Hyperlipoproteinemia medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 13: Line 13:
#*[[Hyperlipidemia statins in children and adolescents with hyperlipidemia | Statins]]
#*[[Hyperlipidemia statins in children and adolescents with hyperlipidemia | Statins]]
#[[Hyperlipidemia NCEP guidelines for adjuvant therapies in children and adolescents | Adjuvant therapies]]
#[[Hyperlipidemia NCEP guidelines for adjuvant therapies in children and adolescents | Adjuvant therapies]]
===[[Omega-3 fatty acids | Omega-3 Fatty Acids]]===
{|class="wikitable" border="1" style="width:750px"
|-style="background:#CDC9C9"
|''' Drug '''
|''' Mechanisms of Benefit '''
|''' Dosage '''
|''' Advantages '''
|''' Side Effects '''
|''' Contraindications '''
|-
| '''Omega-3 fatty acids'''
|
↓ hepatic [[lipogenesis]]<br>↓ plasma [[lipoprotein lipase]] activity<br>↑ hepatic mitochondrial and peroxisomal [[beta-oxidation]]<br>Inhibition of acyl CoA:1,2-[[diacylglycerol acyltransferase]] enzyme<br>[[EPA]] and [[DHA]] are poor enzyme substrates for [[triglyceride]] synthesis in [[liver]] and inhibits esterification of other fatty acids.
|
3 g/day of EPA and DHA<ref name="pmid16825676">{{cite journal| author=Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B et al.| title=n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. | journal=Am J Clin Nutr | year= 2006 | volume= 84 | issue= 1 |pages= 5-17 | pmid=16825676 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16825676  }} </ref>
|
↓ [[VLDL]]<ref name="pmid6736254">{{cite journal| author=Nestel PJ, Connor WE, Reardon MF, Connor S, Wong S, Boston R| title=Suppression by diets rich in fish oil of very low density lipoprotein production in man. | journal=J Clin Invest | year= 1984 | volume= 74 | issue= 1 | pages= 82-9 | pmid=6736254 | doi=10.1172/JCI111422 | pmc=PMC425187 | url=}} </ref>, <ref name="pmid11303007">{{cite journal| author=Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA et al.| title=An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. |journal=Heart | year= 2001 | volume= 85 | issue= 5 | pages= 544-8 | pmid=11303007 | doi= | pmc=PMC1729738 | url= }}</ref><br>↓ [[TG]] by ≥50%
|
[[Bleeding]], at high doses<br>
Fishy smell, can be reduced by
*freezing of medication
*trying different formulation
*taking medication with food
[[Nausea]]
|
Hypersensitivity
|} (↑ - Increase, ↓ - Decrease)


==References==
==References==

Revision as of 18:34, 30 October 2012

Lipoprotein Disorders Microchapters

Patient Information

Overview

Causes

Classification

Hyperlipoproteinemia
Hypolipoproteinemia

Treatment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hardik Patel, M.D.

Overview

Hyperlipidemia requires early detection, careful evaluation and aggressive treatment with combination of therapeutic lifestyle changes and lipid-lowering drug therapies to reduce the risk of cardiovascular and cerebrovascular complications.

Medical Therapy

Medical Therapy in Adults

Medical Therapy in Children and Adolescents

  1. Drug therapy
  2. Adjuvant therapies

References

Template:WH Template:WS